ClinOne and Virtual Clinical Trials: A Natural Fit

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

Clinical trials are crucial for new product and device development and are required by the Food and Drug Administration (FDA) before approvals can be granted for their use in the general population. Overall success is dependent on sponsors to supply clinically valid protocols, active participation of engaged sites, and adequate numbers of potential subjects who fit the inclusion/exclusion criteria and are able to participate through the study’s conclusion, are mandatory for the overall success of any study and the ability to answer the defined research problem. But what if technology could assist with bringing a trial directly to the patient?

What critical elements would need to be covered by the technology to accomplish a virtual clinical trial? The solution requires the ability to manage consent and re-consent practices, management of ePRO, real time collection of clinical data, management of dosing administration and compliance of investigational product or devices and facilitate ongoing study communication and documentation.

ClinOne’s platform includes managing all of these critical elements, allowing patients to manage the majority of their trial experience from the comfort of their own homes. Reducing physical site visits means saving millions of dollars on investigational site budgets. It also means that patients’ compliance rates and reduction of burden are completely transformed – the trial comes to the patients at a fraction of the cost of a traditional study. Sponsors are connected and engaged with their patients versus the significant separation between the two under the current model.

“The significant variance on site quality can be eliminated. The dependency on coordinators can be eliminated, and the level of care can be profoundly improved for patients,” according to Rob Bohacs, ClinOne’s CEO. We realize that many trials are not designed to function outside of a research site today; however, many studies including registry studies, can be managed in a near virtual capacity.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.